α-Adrenergic inhibition of proliferation in HepG2 cells stably transfected with the α1B-adrenergic receptor through a p42MAP kinase/p21Cip1/WAF1-dependent pathway  by Auer, Kelly L et al.
K-Adrenergic inhibition of proliferation in HepG2 cells
stably transfected with the K1B-adrenergic receptor through a
p42MAPkinase/p21Cip1=WAF1-dependent pathway
Kelly L. Auerb, Mark S. Spectora, Robert M. Tombesc, Prem Sethd, Paul B. Fishere,
Bin Gaoa, Paul Dentb;a;*, George Kunosa
aDepartment of Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23298, USA
bDepartment of Radiation Oncology, Medical College of Virginia, Box 980058, Virginia Commonwealth University, Richmond, VA 23298, USA
cDepartment of Biology, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23298, USA
dBreast Cancer Section, Medicine Branch, National Cancer Institute, Building 10, Bethesda, MD 20892, USA
eDepartment of Urology and Pathology, Columbia University College of Physicians and Surgeons, 630 W168th Street, New York, NY 10032, USA
Received 15 July 1998; revised version received 20 August 1998
Abstract Activation of K1B adrenergic receptors (K1BAR)
promotes DNA synthesis in primary cultures of hepatocytes,
yet expression of K1BAR in hepatocytes rapidly declines during
proliferative events. HepG2 human hepatoma cells, which do not
express K1BAR, were stably transfected with a rat K1BAR
cDNA (TFG2 cells), in order to study the effects of maintained
K1BAR expression on hepatoma cell proliferation. TFG2 cells
had a decreased rate of growth compared to mock transfected
HepG2 cells as revealed by a decrease in [3H]thymidine
incorporation into DNA. Stimulation of K1BAR with phenyl-
ephrine caused a further large reduction in TFG2 cell growth,
whereas no effect on growth was observed in mock transfected
cells. Reduced cell growth correlated with increased percentages
of cells found in G0/G1 and G2/M phases of the cell cycle. In
TFG2 cells, phenylephrine increased p42MAPkinase activity by
1.5- to 2.0-fold for up to 24 h and increased expression of the
cyclin dependent kinase inhibitor protein p21Cip1=WAF1. Treat-
ment of TFG2 cells with the specific MEK1 inhibitor PD98059,
or infection with a 3/3 MEK1 recombinant adenovirus
permitted phenylephrine to increase rather than decrease
[3H]thymidine incorporation. In addition, inhibition of MAP
kinase signaling by PD98059 or MEK1 3/3 blunted the ability
of phenylephrine to increase p21Cip1=WAF1 expression. In
agreement with a role for increased p21Cip1=WAF1 expression
in causing growth arrest, infection of TFG2 cells with a
recombinant adenovirus to express antisense p21Cip1=WAF1
mRNA blocked the ability of phenylephrine to increase
p21Cip1=WAF1 expression and to inhibit DNA synthesis. Anti-
sense p21Cip1=WAF1 permitted phenylephrine to stimulate DNA
synthesis in TFG2 cells, and abrogated growth arrest. These
results suggest that transformed hepatocytes may turn off the
expression of K1BARs in order to prevent the activation of a
growth inhibitory pathway. Activation of this inhibitory pathway
via K1BAR appears to be p42MAPkinase and p21Cip1=WAF1
dependent.
z 1998 Federation of European Biochemical Societies.
1. Introduction
K1-Adrenergic receptors (K1AR) are members of the G pro-
tein-coupled receptor superfamily. Through pharmacological
and molecular cloning studies multiple subtypes of K1AR
have been identi¢ed: K1A=CAR, K1BAR and K1DAR [1]. The
rat liver only expresses the K1BAR subtype, which is primarily
coupled to phospholipase C (PI-PLC) via a pertussis toxin-
insensitive G-protein [2,3]. Upon activation, PLC catalyzes
the breakdown of polyphosphatidylinositol-4,5-bisphosphate
(PIP2) to yield two second messengers: inositol tris-phospate
(IP3) which subsequently releases intracellular calcium, and
1,2-diacylglycerol (DAG), which can activate protein kinase
C (PKC) [4]. The K1BAR is also coupled to several down-
stream signaling cascades such as the c-Jun NH2-terminal
kinase (JNK) and the mitogen activated protein kinase
(MAPK) pathways [5,6].
The K1BAR plays an important role in the sympathoadrenal
response to stress, including the acute e¡ects of catechol-
amines on liver carbohydrate, lipid, and amino acid metabo-
lism [7]. In addition to these short-lived e¡ects, the K1BAR
may also mediate the co-mitogenic e¡ect of catecholamines in
the liver. For example, activation of K1BARs increases DNA
synthesis in primary cultures of hepatocytes [5,8] and their
inhibition delays liver regeneration [9]. Activation of K1BAR
can also promote malignant cell growth, as suggested by the
agonist-dependent focus formation and disordered growth ob-
served in Rat-1 ¢broblasts transfected with K1BAR, or the
tumorigenic e¡ect of transplanting cells bearing transfected
K1BARs into nude mice [10].
Activation of the MAP kinase (MAPK) cascade has been
implicated in proliferative signaling in various cell types
[11,12]. However, in primary cultures of rat hepatocytes the
K1BAR-induced increase in DNA synthesis was found to be
relatively independent of MAPK activation, and it was in-
stead coupled to activation of the p38 stress activated protein
(SAP) kinase [5].
Paradoxically, quiescent hepatocytes express much higher
levels of K1BAR than proliferating hepatocytes, as observed
in cells in primary culture [13,14], in the remnant liver follow-
ing partial hepatectomy [7,15,16], and in fetal [17] or malig-
nantly transformed liver [18]. The mechanism(s) by which
proliferating hepatocytes lose K1BAR expression are unclear.
A number of clonal human liver tumor cell lines, including
HepG2 cells, lack functional K1ARs altogether [19]. These
¢ndings could suggest that despite the mitogenic e¡ect of
K1BAR activation in the early stages of the regenerative re-
sponse of the normal liver, continued activation of K1AR may
interfere with the maintenance of high rates of hepatocyte
proliferation in liver tumor cells. In order to test this hypoth-
esis, we generated a HepG2 hepatoma cell line that stably
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expresses the rat K1BAR at high levels (TFG2 cells). We
present evidence that stimulation of K1BAR in TFG2 cells
inhibits their growth via a p42MAPkinase and p21Cip1=WAF1 de-
pendent mechanism.
2. Materials and methods
2.1. Materials
Dominant negative (3/3) MEK1, p21Cip1=WAF1 sense and antisense
adenoviruses were generated as described [20^22]. Anti-p42 MAP kin-
ase (sc-154AC), anti-cdk2 (sc-163), anti-p16INK4a (sc-1207), anti-
p21Cip1 (sc-397-G), anti-p27Kip1 (sc-527-G), anti-cyclin A-(sc-596),
anti-cyclin D-(sc-753), and anti-cyclin E-(sc-481) antibodies were
from Santa Cruz Biotechnologies (Santa Cruz, CA, USA). Radiola-
belled [Q-32P]ATP and [3H]thymidine were from NEN (Boston, MA,
USA). Protein preparations of other reagents were as in [5,23]. The
speci¢c MEK1/2 activation inhibitor PD98059 [24] was a gift from
Parke Davis/Warner Lambert. Wild-type HepG2 human hepatoma
cells were obtained from ATCC (Rockville, MD, USA) and cultured
under conditions speci¢ed by the supplier. The TFG2 cell line was
cultured under the same conditions as the naive HepG2 cells, except
for the additional presence of 50 Wg/ml geneticin to maintain selection
pressure (see below).
2.2. Partial hepatectomy
Adult male Sprague-Dawley rats were subjected to 2/3 partial hep-
atectomy under aseptic conditions. The rats were anesthetized with
sodium pentobarbital, 50 mg/kg i.p., and the median and left lateral
lobes of the liver were ligated at their stem and excised. Control rats
were subjected to sham operation, which consisted of laparotomy and
a brief manipulation of the intestines but not the liver with a cotton
swab prior to wound closure.
2.3. Primary culturing of rat hepatocytes
For isolation of primary cultured rat hepatocytes, male Sprague-
Dawley rats weighing 80^120 g were anesthetized with sodium pento-
barbital, 50 mg/kg intraperitoneally, and the portal vein cannulated
under aseptic conditions. Liver cells were isolated by a collagenase
perfusion protocol as described earlier [25]. The isolated cells were
washed twice with hepatocyte wash medium (Gibco), and plated
onto polylysine-coated culture dishes in attachment medium (Gibco).
After 3 h, the medium was changed to DMEM containing 5% fetal
bovine serum, 1U1038 M dexamethasone, 10 ng/ml EGF, 5 Wg/ml
insulin, 2.5 Wg/ml fungizone, 50 Wg/ml geneticin, 67 Wg/ml penicillin,
and 100 Wg/ml streptomycin.
2.4. Construction of plasmids
The K1BAR expression vector was prepared by subcloning the rat
K1BAR cDNA (3240 to +1676) [26] into the pcDNA3 expression
vector (Invitrogen, CA, USA).
2.5. Transient and stable transfections
Transient transfections were performed by using the lipofectin re-
agent (Gibco), as described previously [16,26]. Brie£y, the HepG2 cells
were grown in six-well culture plates to about 50^60% con£uency. The
DNA to be transfected was then introduced along with the lipofectin
reagent to the cultures in reduced-serum medium OPTI-MEM (Gib-
co). After 16 h the medium was replaced with normal growth medium.
Assays were performed 48 h post transfection. To achieve stable
transfection, cells were treated in the same manner as in transient
transfections, with a few exceptions. These cells were grown to 30^
50% con£uency, and after transfection they were exposed to a selec-
tive concentration (as determined by a ‘killing curve’) of 375 Wg/ml of
geneticin (G418-sulfate, Gibco) to isolate stably transfected cells. Pos-
itive colonies were passaged three more times before selecting unique
clones. The stably transfected cell lines were maintained under con-
stant selection pressure in the continued presence of 375 Wg/ml genet-
icin.
2.6. Adenoviral infection of HepG2 cells
HepG2/TFG2 cells (in DMEM, 10% (v/v) fetal calf serum (FCS),
60-mm dishes, 106 cells) were washed with medium (DMEM), and the
cells infected with either null recombinant adenovirus or with domi-
nant negative (3/3) MEK1, p21Cip1=WAF1 sense, or p21Cip1=WAF1 anti-
sense recombinant adenoviruses in a total volume of 1 ml and at a
multiplicity of infection of 200. After 2 h at 37‡C, the cells were
washed with DMEM and cultured for a further 24 h prior to exper-
imentation in DMEM containing 10% (v/v) FCS.
2.7. Treatment of HepG2 cells and primary hepatocytes for kinase
assays
Primary hepatocytes (2U105 cells per well of a 12-well dish) were
cultured in DMEM containing 100 nM insulin, 1 nM dexamethasone,
1 nM thyroxine [21]. Cells were cultured for 90 min after isolation
prior to assay. This was to allow stabilization of protein kinase activ-
ities, which may have been a¡ected by the isolation process. In addi-
tion, prolonged culture of primary hepatocytes (V12^24 h) causes a
decrease in K1B-adrenergic receptor expression. HepG2 cells were
grown to near con£uency in 100-mm dishes, and 2 h prior to the
kinase assays they were serum starved in DMEM containing 100 nM
insulin, 1 nM dexamethasone and 1 nM thyroxine.
Drugs were added directly to the medium for the speci¢ed periods
of time and ¢nal concentrations for each cell type. Thirty seconds
prior to terminating the incubation, the medium was aspirated and
the dishes were placed on dry ice. After the addition of 400 Wl of ice-
cold homogenization bu¡er (25 mM HEPES, pH 7.4, 5 mM EDTA,
5 mM benzamidine, 1 mM PMSF, 1 mg/ml soybean trypsin inhibitor,
40 Wg/ml pepstatin A, 40 Wg/ml aprotinin, 1 WM microcystin-LR,
0.5 mM sodium orthovanadate, 0.5 mM sodium pyrophosphate, 1%
(v/v) Triton X-100, 0.1% 2-mercaptoethanol), cells were collected with
a rubber policeman. Samples were stored on ice for 5 min prior to
centrifugation (14 000Ug, 5 min, 4‡C).
2.8. Immunoprecipitations from cell homogenates
The protein A agarose slurry (25 Wl bead volume) was washed with
1.0 ml PBS containing 0.1% (v/v) Tween 20, and resuspended in 0.4 ml
of the same bu¡er. Antibodies (2 Wg, 20 Wl) were added to each tube
and incubated (2 h, 4‡C) to allow for their conjugation to the protein-
A agarose beads, followed by a subsequent wash to remove non-con-
jugated antibodies. The supernatant from the homogenates (0.5 ml,
0.5 mg total protein for both HepG2 cells and primary hepatocytes)
was mixed with protein A agarose-conjugated antibody and incubated
on a rocking mixer (2 h, 4‡C). The protein A agarose was recovered
by centrifugation, the supernatant discarded, and the immunoprecipi-
tates were washed twice with homogenization bu¡er and once with
washing bu¡er (25 mM HEPES, pH 7.4, 15 mM MgCl2, 0.1 mM
sodium orthovanadate, 0.1% 2-mercaptoethanol).
2.9. Assay of p42MAPK activity
The assay for p42MAPK activity was described previously [5,21].
Brie£y, immunoprecipitates were incubated (¢nal volume 50 Wl) with
50 Wl of washing bu¡er containing 0.2 mM [Q-32P]ATP (5000 cpm/
pmol), 1 WM microcystin-LR, and 0.5 mg/ml myelin basic protein
(MBP) ^ the substrate for p42MAPK. Following a 20-min incubation
at 37‡C, 40 Wl of the reaction volume was spotted onto P81 paper
(Whatman, Maidstone, UK) and immediately placed into 180 mM
phosphoric acid. The papers were washed several times in 180 mM
phosphoric acid, followed by a ¢nal wash with acetone. The 32P in-
corporation into MBP was quanti¢ed by liquid scintillation spectrom-
etry.
2.10. Assay of cyclin dependent kinase 2 (cdk2) activity
Cdk2 activity was measured in immunoprecipitates of whole cell
lysates. TFG2 cells were rinsed with PBS/5 mM EGTA, then har-
vested in homogenization bu¡er (described above) containing 0.5%
NP-40. Samples were sonicated (two 5-s bursts on ice), centrifuged
at 13 000Ug for 15 min at 4‡C and either assayed immediately or
stored at 370‡C. In lysates prepared by sonication, over 90% of the
total CaMK-II activity or pRb was solubilized, as measured by sol-
ution assays and immunoblots. Approximately 100 Wg of cellular pro-
tein from whole cell homogenates was incubated sequentially with 1 Wg
of puri¢ed rabbit anti-cdk2 IgG, followed by 2 Wg of biotinylated goat
anti-rabbit IgG (Molecular Probes, Eugene, OR, USA) and ¢nally
streptavidin-magnespheres (Promega, Madison, WI, USA) on ice in
200 Wl for at least 2 h each. Immune complexes were washed 3 times
with 30 mM HEPES, pH 7.4, 15 mM MgCl2, 80 mM L-glycerol
phosphate, 2.6 mM EGTA, 1 Wg/ml each of chymostatin, leupeptin,
antipain, pepstatin and soybean trypsin inhibitor, 0.5% NP-40, and
then resuspended in 25 Wl of the same bu¡er without NP-40. Protein
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kinase assays were conducted by assaying 10 Wl of these immunopre-
cipitated samples in triplicate in a total volume of 25 Wl, containing
¢nal concentrations of 30 mM HEPES, pH 7.4, 0.1 mM DTT, 25 mM
MgCl2, 30 mM L-glycerol phosphate, 0.5 WM protein kinase A inhib-
itor peptide (TTTADFIAGRRNAIHD), 0.5 WCi [Q-32P]ATP and 20
WM ATP, 2 mM EGTA and 0.5 mg/ml histone H1. After 10^20 min
at 32‡C, assays were stopped by pipetting 20 Wl of the mixture onto
P81 phosphocellulose paper (Whatman, Clifton, NJ, USA), air dried
for 1 min and then washed 5 times in 500 ml 1% phosphoric acid. The
retained radioactivity was quanti¢ed by Cerenkhov counting.
2.11. [3H]Thymidine incorporation
Following preincubation of the cells with an antagonist (if applica-
ble), [3H]thymidine (2^10 WCi/ml) was added to the culture along with
the appropriate agonist at 24 h after plating. Cells were incubated for
a further 3 h at 37‡C. The cells were dissolved by the addition of
1.0 ml 0.5 N NaOH, collected, mixed with 1.5 ml H2O, and pre-
cipitated with 0.5 ml of 50% trichloroacetic acid (TCA). The pre-
cipitated material was collected on glass ¢ber ¢lters and washed twice
with 5% TCA, followed by liquid scintillation counting of the ¢lters.
2.12. Western blotting
Visualization of proteins by Western immunoblotting was done as
described in detail elsewhere [5,16,21].
2.13. Preparation of crude nuclear extracts
Methods for preparing crude nuclear extracts from cultured cells
were adapted from [27]. Brie£y, cells were washed in PBS bu¡er and
collected with a rubber policeman in 500 Wl extract bu¡er (20 mM
HEPES, 450 mM NaCl, 0.4 mM EDTA, 25% glycerol, 0.5 mM DTT,
0.5 mM PMSF). The cells were subjected to three cycles of freeze-
thawing, followed by centrifugation at 14 000Ug for 10 min. Protein
in the supernatant was determined by using the Bio-Rad protein as-
say, using BSA as standard.
2.14. DNA gel mobility shift assay
DNA gel mobility shift assays (GMSA) were carried out as previ-
ously described [16,26].
2.15. Receptor binding assay
K1BAR in stably transfected and mock transfected HepG2 cells
were identi¢ed by an equilibrium binding assay using [3H]prazosin
as the radioligand [25]. Cells were subjected to one cycle of freeze-
thawing to reduce non-speci¢c binding, and were then suspended in
50 mM Tris-HCl/10 mM MgSO4 bu¡er at pH 7.4. Triplicate aliquots
containing 100 Wg protein and a saturating concentration of
[3H]prazosin (20 nM) in the absence (total binding) or presence of
10 WM phentolamine (non-speci¢c binding) were incubated for 50 min
at 30‡C in a total volume of 1.0 ml. Incubations were terminated by
rapid vacuum ¢ltration over Whatman GF/B ¢lters presoaked in as-
say bu¡er, and the radioactivity retained by the ¢lters was measured
by liquid scintillation spectrometry. For generating displacement iso-
therms, cells were incubated with 1 nM [3H]prazosin in the absence or
presence of 8^12 concentrations of the unlabeled competing ligand.
Competitor and radioligand were added to the assay simultaneously,
except for chloroethylclonidine, which was added to the cell prepara-
tion 15 min prior to the addition of the radioligand. Kds of the com-
petitor ligands were derived by computerized curve-¢tting, using the
ALLFIT program.
2.16. Cell cycle analysis: propidium iodide staining of cells
Cells were grown on plates during various treatments and were
isolated by tryptic digestion, followed by pelleting by centrifugation
at 1500 rpm, 4‡C for 5 min and resuspended in 1.5 ml of PBS fol-
lowed by the addition of 3 ml of 100% ETOH (67% ETOH Fix) and
incubated on ice at 4‡C for at least 1 h. Cells were pelleted by cen-
trifugation as above, supernatant removed and resuspended in 1.0 ml
of propidium iodide stain containing 3.8 mM sodium citrate, 0.5 mg/
ml RNase A and 0.01 mg/ml propidium iodide and incubated on ice
at 4‡C for 3 h. Cells were pelleted by centrifugation as above, super-
natant removed and resuspended in 1.0 ml of PBS and ready for
analysis. Cells were analyzed with a Becton-Dickinson FACScan
£ow cytometer and Verity Winlist software.
2.17. Data analysis
Comparison of the e¡ects of various hormone treatments was per-
formed using one way analysis of variance and a two tailed t-test.
Di¡erences with a P-value of 6 0.05 were considered statistically sig-
ni¢cant. Experiments shown are the means of 3^6 individual exper-
iments þ S.E.M. performed in duplicate.
3. Results
3.1. Expression of K1BAR in TFG2 cells
To measure the cellular density of K1BAR, ligand binding
assays were performed using TFG2 cells (HepG2 cells stably
transfected with K1BAR cDNA) as well as mock transfected
HepG2 cells. In TFG2 cells, K1BARs were expressed at a high
level (2150 þ 150 fmol/mg total cellular protein) compared to
either negligible levels of K1BAR in mock transfected HepG2
cells (6 5 fmol/mg protein) or lower levels of expression in
freshly isolated hepatocytes (125 þ 5 fmol/mg protein). Dis-
placement of the radioligand by unlabeled competitor drugs
displayed binding speci¢city expected from K1BAR (Fig. 1).
The K1BAR-selective ligand WB-4101 displaced [3H]prazosin
with high a⁄nity (Kd of 10 nM), whereas the a⁄nities of the
K1AAR-selective ligands, niguldipine, oxymethazoline and 5-
methylurapidil, were much lower (Kdss 1^30 WM). The
K1BAR-selective irreversible antagonist, chloroethylclonidine,
was able to completely displace [3H]prazosin binding, with an
apparent Kd of 10 WM.
3.2. Activation of K1AR in TFG2 cells inhibits DNA synthesis
and cell proliferation
We next examined the ability of phenylephrine (PE) to af-
fect the rate of DNA synthesis and cell division in TFG2 cells,
and compared these e¡ects to those observed in primary cul-
tured rat hepatocytes [28,29]. Treatment of primary cultures
of adult rat hepatocytes with di¡erent concentrations of PE
resulted in a concentration-dependent increase in
[3H]thymidine incorporation into primary hepatocyte DNA
(Fig. 2A), which is in agreement with previously published
¢ndings [5]. In contrast, treatment of TFG2 cells with PE,
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Fig. 1. Ligand binding to K1B-adrenergic receptors stably transfected
in TFG2 cells. TFG2 cells were cultured and radioligand binding
displacement studies were performed as in Section 2. Note that the
K1B-adrenergic receptor-selective ligand WB-4101 (F) displaced
[3H]prazosin with high a⁄nity (Kd of 10 nM), whereas the a⁄nities
of the K1AAR-selective ligands, niguldipine (b), oxymethazoline (a)
and 5-methylurapidil (R), were much lower (Kdss 1^30 WM). Com-
plete displacement by chloroethylclonidine (j, apparent Ki : 10 WM)
is also compatible with a pure population of K1B receptors. Data
shown are means of 3 independent experiments.
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EPI or NE caused concentration-dependent decreases in
[3H]thymidine incorporation into DNA, which were com-
pletely prevented by 1 WM prazosin (Fig. 2B). The ability of
PE treatment to inhibit DNA synthesis was not blocked by
pertussis toxin pre-treatment (100 ng/ml, 24 h) of the cells (not
shown).
In additional experiments, cell counts over a ¢ve-day period
also indicated corresponding changes in cell growth. TFG2
cells grew at a signi¢cantly slower rate (69 þ 3%) than mock
transfected HepG2 cells, and their rate of growth was further
signi¢cantly reduced in the presence of PE alone, but not in
the presence of PE plus the antagonist prazosin (60 þ 5% and
100 þ 4%, respectively, of untreated TFG2 cells). Since the
expression and function of the K1BAR declines within a few
hours of primary culturing in rat hepatocytes [5,16], whereas it
always remains high in TFG2 cells, the above ¢ndings suggest
that the prolonged ability of adrenergic agonists to signal
through K1BAR may be anti-proliferative in hepatocytes.
To con¢rm that cell cycle arrest in response to phenyleph-
rine treatment had occurred, £ow cytometric analysis was
performed on TFG2 cells 48 h after addition of phenylephrine
to the media. In untreated cells, 63 þ 4% of cells were in
G0/G1 ; 31 þ 2% of cells were in S phase; and 6 þ 1% of cells
were in G2/M phase. However, in TFG2 cells treated with
10 WM phenylephrine, 83 þ 3% of cells were in G0/G1 phase;
3 þ 1% of cells were in S phase; and 14 þ 2% of cells were in
G2/M phase. These data demonstrate that phenylephrine
causes cell cycle arrest in both G0/G1 and G2/M phases of
the cell cycle.
We recently demonstrated that PE acting through the
K1BAR increases the activity of p42MAPK in primary cultured
rat hepatocytes [5]. Others have reported that prolonged acti-
vation of the MAPK cascade can inhibit DNA synthesis in
various types of cells [30], including primary cultures of rat
hepatocytes [5]. We next tested whether PE can stimulate the
activity of the MAPK cascade in TFG2 cells, and whether this
activation may account for the ability of PE to inhibit DNA
synthesis in these cells.
3.3. Phenylephrine causes prolonged activation of the MAPK
cascade in TFG2 cells
We tested the e¡ect of PE on p42MAPK activity in primary
cultures of rat hepatocytes, as well as in TFG2 and mock
transfected HepG2 cells. HepG2 cells had a very high basal
MAPK activity in comparison to primary hepatocytes without
signi¢cant alteration in the relative protein expression of
p42MAPK (Fig. 3, data not shown). Transfection of HepG2
cells with the K1BAR had little e¡ect on basal MAPK speci¢c
activity. PE treatment of TFG2, but not mock transfected,
cells caused a further V2-fold increase in p42MAPK speci¢c
activity, which remained elevated for up to 24 h (Fig. 3). In
contrast, primary hepatocytes which had been in culture
for 90 min possessed a much lower basal p42MAPK activity
than HepG2 cells, and responded to PE treatment by a tran-
sient, V5-fold increase in MAPK speci¢c activity which
lastedV20 min before returning to basal levels (Fig. 3). These
data are in general agreement with those obtained earlier in
freshly isolated hepatocytes [5]. The PE-dependent activation
of p42MAPK was similarly increased in TFG2 cells by NE and
EPI, and the e¡ects of all 3 agonists were blocked by prazosin
(data not shown).
3.4. Prolonged activation or prolonged inhibition of MAPK
signaling has anti-proliferative e¡ects in TFG2 cells
To determine if the agonist-induced changes in growth rate
in TFG2 cells were p42MAPK dependent, TFG2 cells were
treated with PE in the presence of either the speci¢c MEK1
inhibitor, PD98059 (50 WM), or in cells infected with a dom-
inant negative (3/3) MEK1 recombinant adenovirus. Basal
p42MAPK activity was decreased by V80% after either the
addition of 50 WM PD98059 or infection with the 3/3
MEK1 adenovirus, which con¢rms that signaling by the
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Fig. 2. Phenylephrine increases DNA synthesis in primary cultured rat hepatocytes and inhibits DNA synthesis in TFG2 cells. Freshly isolated
rat hepatocytes (A) and TFG2 cells (B) were cultured as in Section 2. Cells were treated with either vehicle, the indicated adrenergic agonist,
or agonist plus prazosin (Pz, 1 WM) as indicated, together with 2 WCi [3H]thymidine. Forty eight hours after the addition of drug(s) and
[3H]thymidine, cells were harvested and [3H]thymidine incorporation into DNA determined. Means and S.E. of 3 separate experiments are
shown. # indicates signi¢cant increase and * indicates signi¢cant decrease (P6 0.05) from corresponding drug-free control (C).
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p42MAPK pathway was blocked by both of these treatments
(data not shown). Treatment of TFG2 cells with PD98059 or
expression of 3/3 MEK1 decreased DNA synthesis, suggest-
ing that MAPK activity plays a role in maintaining the basal
rate of growth in these cells (in agreement with data in [5,21]).
Treatment of TFG2 cells with PE also decreased DNA syn-
thesis (Fig. 4A). In contrast, co-treatment of TFG2 cells with
PE and either PD98059 or 3/3 MEK1 returned DNA syn-
thesis back to near-control levels (Fig. 4A). Thus a reduction
in the ability of PE to stimulate p42MAPK activity prevented
PE from inhibiting DNA synthesis, and reversed the inhibi-
tory e¡ects of PD98059 and 3/3 MEK1 on basal DNA syn-
thesis. Based on our data in primary hepatocytes, it is possible
that other PE-stimulated pathways, e.g. p38SAPkinase, play a
role in the ability of the agonist to stimulate proliferation
when MAPK activity is reduced [5]. These observations sug-
gest that the K1BAR-mediated inhibition of DNA synthesis in
TFG2 cells is p42MAPK dependent.
3.5. Prolonged activation of the MAPK cascade in TFG2 cells
induces the cyclin dependent kinase inhibor (CKI) protein,
p21Cip1=WAF1, by a MAPK-dependent mechanism
Prolonged elevation of MAPK activity has been reported to
decrease DNA synthesis via induction of cyclin dependent
kinase inhibitor (CKI) proteins in other cells [21,28,29]. Since
PE treatment of TFG2 cells also caused prolonged MAPK
activation and inhibited DNA synthesis, we next examined
the ability of PE to increase expression of CKI proteins via
the MAPK cascade. PE treatment of TFG2 cells, but not
mock transfected cells or primary hepatocytes, increased ex-
pression of p21Cip1=WAF1 (Fig. 4B), but not p16INK4A, and
reduced p27Kip1 expression (data not shown), as tested by
Western blotting. Pretreatment of cells with either PD98059
or expression of 3/3 MEK1 adenovirus blocked the ability of
PE to increase p21Cip1=WAF1 expression. Treatment of the cells
with PE, PD89059, or 3/3 MEK1 adenovirus had little e¡ect
upon the expression of cyclins A, D1 or E (data not shown).
To further analyze the observed inhibitory pathway, we
examined the ability of PE to modulate the activity of the
cyclin dependent kinase cdk2, whose function is essential for
progression from G1 to S phase [31]. Treatment of TFG2 cells
with PE dramatically reduced cdk2 activity in assays using
histone H1 as substrate, from 5.40 þ 0.5 to 0.70 þ 0.06 pmol/
mg/min, which is in agreement with the observed induction of
p21Cip1=WAF1 by the same treatment. In further agreement
with the data in Fig. 4, treatment of TFG2 cells with
PD98059 alone decreased cdk2 activity to 1.10 þ 0.02 pmol/
mg/min. However, co-treatment of cells with PE and PD98059
increased cdk2 activity to 1.90 þ 0.20 pmol/mg/min. These
data suggest that PE stimulates a growth promoting pathway
that is masked in TFG2 cells by increased growth inhibitory
MAPK signaling.
To more conclusively test the role of the CKI p21Cip1=WAF1
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Fig. 4. Phenylephrine, via an MAPK dependent mechanism, inhibits
DNA synthesis in TFG2 cells by increasing expression of the cyclin
dependent kinase inhibitor protein p21Cip1=WAF1. TFG2 cells were
cultured as in Section 2. Twenty four hours prior to hormone addi-
tion, a portion of the cells was infected with a recombinant adenovi-
rus to express dominant negative MEK1 (3/3 MEK). Thirty min-
utes prior to addition of 10 WM phenylephrine (PE)+2 WCi
[3H]thymidine, aliquots of the cells were treated with either vehicle
or 50 WM PD98059 (PD). Cells were harvested 48 h later, with one
aliquot used for determination of [3H]thymidine incorporation into
DNA (A), and a second aliquot used for Western blotting with
anti-p21Cip1 (B), as described in Section 2. Note that PE inhibits
DNA synthesis in TFG2 cells, which is overcome by MAPK inhibi-
tion (A), and increases the expression of the cdk inhibitor protein
p21Cip1=WAF1 in an MAPK-dependent fashion (B). Data in A are the
mean of 3 separate experiments.
Fig. 3. Phenylephrine causes transient or prolonged activation of
MAPK in primary hepatocytes or TFG2 cells, respectively. Primary
hepatocytes (F), control transfected HepG2 cells (S), and TFG2
cells (b) were cultured as described in Section 2. Cells were treated
with phenylephrine (10 WM) and p42MAPK was determined at the in-
dicated times (0^24 h), as described in Section 2. Data are means of
duplicate values (di¡ering by 6 10%) from a representative of three
independent experiments and are expressed as -fold increase in 32P-
incorporation into MBP/min/mg cell protein (speci¢c activity) over
the speci¢c activity of MAPK in primary hepatocytes at zero time.
Basal MAPK speci¢c activity was 0.14 þ 0.01 pmol/min/mg in pri-
mary hepatocytes, 1.52 þ 0.03 pmol/min/mg in control HepG2 cells,
and 1.63 þ 0.02 pmol/min/mg in TFG2 cells.
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in the PE/MAPK-mediated growth arrest response, we in-
fected cells with recombinant adenoviruses to express either
p21Cip1=WAF1 antisense mRNA, p21Cip1=WAF1 protein, or with
control virus (Fig. 5). In HepG2 cells, expression of
p21Cip1=WAF1 protein blunted DNA synthesis compared to
cells infected with control virus (Fig. 5B), whereas expression
of p21Cip1=WAF1 antisense mRNA had little e¡ect on growth
(Fig. 5A). In these cells, PE did not in£uence thymidine up-
take in any of the 3 treatment groups (Fig. 5A), and failed to
induce p21Cip1=WAF1 expression, as tested in the control group
only (Fig. 5B).
However, in TFG2 cells infected with the control virus, PE
inhibited DNA synthesis (Fig. 5A) and increased p21Cip1=WAF1
expression (Fig. 5B). In TFG2 cells expressing the
p21Cip1=WAF1 antisense mRNA, PE failed to induce
p21Cip1=WAF1 expression (Fig. 5B) and stimulated rather than
inhibited DNA synthesis (Fig. 5A). Expression of
p21Cip1=WAF1 protein in TFG2 cells inhibited baseline DNA
synthesis, which was further inhibited by PE treatment (Fig.
5A). These data suggest that inhibition of DNA synthesis via
activation of K1B receptors is a MAPK/p21Cip1=WAF1-depend-
ent event.
To con¢rm by an independent methodology that expression
of p21Cip1=WAF1 mRNA abrogates cell cycle arrest in response
to phenylephrine treatment, £ow cytometric analysis was per-
formed on TFG2 cells 48 h after addition of phenylephrine to
the media. In untreated cells infected with antisense
p21Cip1=WAF1, 62 þ 6% of cells were in G0/G1 ; 30 þ 2% of cells
were in S phase; and 8 þ 2% of cells were in G2/M phase. This
data is very similar to that obtained in uninfected TFG2 cells.
In TFG2 cells infected with antisense p21Cip1=WAF1 and treated
with 10 WM phenylephrine, 53 þ 2% of cells were in G0/G1
phase; 37 þ 4% of cells were in S phase; and 10 þ 2% of cells
were in G2/M phase. These data demonstrate that in the pres-
ence of antisense p21Cip1=WAF1, PE does not cause cell cycle
arrest in TFG2 cells.
4. Discussion
The major ¢nding in the present study is that stimulation of
the G protein-coupled K1BAR has an anti-proliferative e¡ect
in a malignant hepatoma cell line continuously expressing the
K1BAR. HepG2 cells, stably transfected with the K1BAR, re-
spond to PE treatment with a decrease in DNA synthesis. The
receptor speci¢city of these e¡ects is indicated by their inhib-
ition by the K1AR antagonist prazosin.
PE treatment of TFG2 cells caused a prolonged activation
of the MAPK cascade. Inhibition of the MAPK cascade by a
selective inhibitor, PD98059, or by the over-expression of
dominant negative 3/3 MEK1 reduced basal TFG2 cell
DNA synthesis and reversed the e¡ect of PE treatment on
DNA synthesis from inhibition to stimulation. This indicates
that the inhibitory e¡ect of PE upon DNA synthesis in TFG2
cells is mediated via the MAPK cascade, which masks a pro-
proliferative, MAPK-independent signal. The independence of
this latter response from MAPK activity is in agreement with
our earlier observations in primary cultured rat hepatocytes,
in which the K1-adrenergic stimulation of DNA synthesis was
signi¢cantly blunted by an inhibitor of the p38SAPkinase, but
only weakly attenuated by an inhibitor of the MAPK path-
way [5]. Our data suggest that prolonged activation or pro-
longed inhibition of the MAPK cascade can both reduce
DNA synthesis in TFG2 cells.
Of note, however, is that over-expression of the K1BAR did
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Fig. 5. Phenylephrine increases DNA synthesis in TFG2 cells infected with a recombinant adenovirus to express antisense p21Cip1=WAF1. Mock
transfected HepG2 cells and TFG2 cells were cultured as in Section 2. Cells were infected with either control adenovirus or p21Cip1=WAF1
recombinant adenoviruses at a multiplicity of infection of 200, 24 h prior to the experiment. Cells were treated with either vehicle (3), or
100 WM of PE (+) as indicated, with 10 WCi [3H]thymidine (A) or with vehicle (B). Twenty four hours after the addition of PE, cells in A were
harvested and [3H]thymidine incorporation into DNA determined, and cells in B were harvested and processed for SDS-PAGE followed by im-
munoblotting to determine p21Cip1=WAF1 expression. Data are the means þ S.E.M. of 3 separate experiments. p indicates signi¢cant di¡erence
from corresponding values in control virus-infected HepG2 cells (P6 0.05); * and # indicate signi¢cant decrease or increase, respectively, from
corresponding vehicle-treated TFG2 cells (P6 0.05), and @ indicates signi¢cant decrease (P6 0.05) from corresponding control virus-infected
TFG2 cells.
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not signi¢cantly increase basal MAPK activity, whilst it did
cause a signi¢cant decrease in proliferative capacity. Thus our
data also argue that increased expression of the unstimulated
K1BAR inhibits HepG2/TFG2 cell growth by an additional,
MAPK-independent, mechanism.
Three lines of evidence suggest that the major anti-prolifer-
ative e¡ect of K1BAR activation in TFG2 cells is mediated via
MAPK activation and increased protein levels of the CKI
p21Cip1=WAF1. First, treatment of cells with PD98059 or the
expression of 3/3 MEK1 reversed the response to K1BAR
stimulation from a growth inhibitory to a growth stimulatory
one, and also increased expression of p21Cip1=WAF1. Second,
increased expression of p21Cip1=WAF1 in TFG2 cells resulted in
decreased cdk2 activity and reduced DNA synthesis. Third,
expression of p21Cip1=WAF1 antisense mRNA abrogated both
the K1BAR-induced increase in p21Cip1=WAF1 expression, the
parallel inhibition of DNA synthesis, and cell cycle arrest.
These ¢ndings strongly suggest that K1BAR stimulation inhib-
its DNA synthesis in TFG2 cells via the MAPK pathway and
p21Cip1=WAF1.
In mammalian cells, the cell division cycle is controlled by
the formation and activation of protein kinase complexes,
consisting of cyclins and cyclin dependent kinases (CDKs)
[32^34]. The CDKs control the cell cycle checkpoints in a
coordinated way, thus ensuring the integrity of the genome
by preventing the replication of damaged DNA [35]. By in-
hibiting the kinase activity of the CDKs, CKI proteins inter-
fere with phosphorylation events critical for cell cycle transi-
tions. For example, it has been shown that over-expression of
p21Cip1=WAF1 can cause cell cycle arrest at the G1/S and G2/M
interfaces, most likely as a result of decreased activity of cy-
clins D and E/cdk2-cdk4 complexes and cyclins A and B/cdc2
complexes, respectively [32^34].
Several studies have suggested that p21Cip1=WAF1 is an im-
portant mediator of growth arrest [36]. Protein levels of
p21Cip1=WAF1 can be elevated by an over-expression of a num-
ber of transcription factors, such as p53 [37], C/EBPK [38], C/
EBPL [39], Sp1 [40], and MyoD [41], but also by treatment of
cells with high concentrations of growth factors and mitogens
[21,28]. In particular, prolonged activation of the MAPK cas-
cade in a variety of transformed and established cell types has
recently been shown to increase p21Cip1=WAF1 expression
[21,28^30]. In some of these studies it was also suggested
that the ability of MAPK signaling to either increase or de-
crease proliferation depended upon the amount of signal gen-
erated [21,28]. Tombes et al. recently demonstrated in primary
hepatocytes that a transient elevation of MAPK activity in-
creased DNA synthesis whereas a prolonged activation of the
cascade caused an increase in p21Cip1=WAF1 expression, and a
decrease in DNA synthesis. The reason why transient and
prolonged MAPK signaling have disparate abilities to in-
crease and decrease growth, respectively, is unclear.
It has also been shown that the MAPK-induced,
p21Cip1=WAF1 dependent cell cycle arrest in G1 can be over-
come in various cell types by co-expression of the SV40 large
T antigen [42] or by use of p21Cip1=WAF1 null cells [30]. These
data suggest that transformation of a primary cell requires the
loss of function of multiple oncogenes/signaling proteins. For
example, malignant transformation is frequently associated
with mutations resulting in constitutively active membrane
receptors and Ras/Raf kinase signaling [43^45]. Our studies
in HepG2 cells suggest that additional mutations resulting in
either receptor inactivation or loss of K1BAR expression may
also have additional growth advantages for hepatoma cells.
Removal of a potential growth inhibitory signal in hepatoma
cells, such as signaling by the K1BAR, will reduce the ability of
these cells to cell cycle arrest. In this respect, it is interesting to
note that a number of malignant hepatoma cell lines have all
been found to be devoid of K1AR [19], which is in sharp
contrast to the high level of K1AR expression in normal liver
tissue. These data are also similar to those obtained in A431
squamous carcinoma cells exposed to epidermal growth factor
(EGF) [46,47]. A431 cells express high levels of the EGF re-
ceptor, and respond to this agonist by undergoing a
p21Cip1=WAF1 mediated growth arrest. Further studies are
aimed to test whether stable transfection of K1BAR into hep-
atoma cells reduces their in vivo tumorigenic potential.
Basal levels of p42MAPK activity were found to be consid-
erably higher in HepG2/TFG2 cells than in primary cultures
of hepatocytes (Fig. 4). As a result, even though the peak
stimulation by PE was greatest in the primary cells, the total
amount of MAPK speci¢c activation induced by catechol-
amines was actually greater in HepG2/TFG2 cells than in
primary hepatocytes. This increase in the amount of MAPK
speci¢c activity in HepG2/TFG2 cells may be responsible for
switching the e¡ect of catecholamine exposure from being
mitogenic to anti-proliferative, in agreement with other pub-
lished observations [5,30].
Data presented by Tombes et al. suggested that a sustained
V4-fold elevation in MAPK activity, toV0.50 pmol/min/mg,
can increase p21Cip1=WAF1 expression in primary hepatocytes
and inhibit DNA synthesis [5]. However, the speci¢c activity
of MAPK in primary hepatocytes which induced p21Cip1=WAF1
in those studies is V3-fold less than the basal unstimulated
speci¢c activity of MAPK in HepG2/TFG2 cells (V1.6 pmol/
min/mg), which do not express signi¢cant levels of
p21Cip1=WAF1 protein (Fig. 5B). Together, these ¢ndings sug-
gest that the threshold at which MAPK signaling can elevate
p21Cip1=WAF1 expression has increased in transformed vs. pri-
mary hepatocytes. An increase in this threshold will potentiate
the ability of MAPK signaling to cause proliferation vs. cell
cycle exit in the transformed hepatocytes. The change in
threshold is unlikely to be due to altered p53 function since
both primary hepatocytes and HepG2/TFG2 cells express
wild-type p53 [48]. Since both primary hepatocytes and
HepG2 cells also express p21Cip1=WAF1, these data suggest
that 353-independent mechanisms downstream of MAPK sig-
naling and upstream of p21Cip1=WAF1 expression may have
become defective during the process of hepatocellular trans-
formation.
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